A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1875 participants.
Also called NCT01347580
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,875 participants
- Sponsor
- Registry
-
NCT01347580
-
- Other papers using this trial's data
- Association between gender and short-term outcome in patients with ST elevation myocardial infraction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis
- Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study
- Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis
- Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine
- P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study
- Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial
- Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population
- Prehospital ticagrelor in ST-segment elevation myocardial infarction
- Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction: Findings from the ATLANTIC trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Algeria, Australia, Austria, Canada, Denmark, France, Germany, Hungary, Italy, Netherlands, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01347580. Randomized; triple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2013-11 (actual). Results posted on 2015-02-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)
- Acronym
- ATLANTIC
- Condition
- Myocardial Infarction
- Condition
- Segment Elevation Myocardial Infarction (STEMI)
- Intervention (Drug)
- Ticagrelor
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct01347580- Content hash
dd9fec55f9cf21ba831b3ad67767302b0c4ae13a9015461366c7860ef6ecddf4